PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34239560-9 2021 In the DM group, serum IGF-I and total IGFBP-3 levels were positively correlated with fasting plasma glucose and HbA1c levels. Glucose 101-108 insulin like growth factor binding protein 3 Homo sapiens 39-46 8971549-1 1996 IGFBP-3 contains a carboxyterminal basic region which, when present as an isolated 18 amino acid peptide (P3), binds heparin, associates with cultured endothelial cells and stimulates glucose uptake. Glucose 184-191 insulin like growth factor binding protein 3 Homo sapiens 0-7 7535669-15 1995 CONCLUSION: These data confirm that subjects with IDDM have reduced serum IGF-I and IGFBP-3 and increased IGFBP-1 levels, the latter being directly related to the fasting plasma glucose concentrations. Glucose 178-185 insulin like growth factor binding protein 3 Homo sapiens 84-91 34558885-2 2021 We previously demonstrated that activated hypoxia-inducible factor-1alpha (HIF-1 alpha)/insulin-like growth factor binding protein-3 (IGFBP-3) signaling by reactive oxygen species (ROS)-regulated prolyl hydroxylase domain-containing protein (PHD) is involved in high-glucose (HG)-induced cardiac apoptosis. Glucose 267-274 insulin like growth factor binding protein 3 Homo sapiens 88-132 34558885-2 2021 We previously demonstrated that activated hypoxia-inducible factor-1alpha (HIF-1 alpha)/insulin-like growth factor binding protein-3 (IGFBP-3) signaling by reactive oxygen species (ROS)-regulated prolyl hydroxylase domain-containing protein (PHD) is involved in high-glucose (HG)-induced cardiac apoptosis. Glucose 267-274 insulin like growth factor binding protein 3 Homo sapiens 134-141 7533774-6 1995 In addition, the response of IGFBP-3 to glucose suppression was investigated. Glucose 40-47 insulin like growth factor binding protein 3 Homo sapiens 29-36 7533774-14 1995 IGFBP-3 and IGF-I levels were concordant with GH suppressibility by glucose (P = 0.0039) and IGFBP-3 decreased with glucose suppression in 7 of 10 patients. Glucose 68-75 insulin like growth factor binding protein 3 Homo sapiens 0-7 7533774-14 1995 IGFBP-3 and IGF-I levels were concordant with GH suppressibility by glucose (P = 0.0039) and IGFBP-3 decreased with glucose suppression in 7 of 10 patients. Glucose 116-123 insulin like growth factor binding protein 3 Homo sapiens 93-100 7533774-15 1995 These data indicate that IGFBP-3 is a sensitive physiological marker of somatotroph function and is concordant with glucose suppression and IGF-I levels before and after transsphenoidal surgery. Glucose 116-123 insulin like growth factor binding protein 3 Homo sapiens 25-32 7682592-6 1993 Recombinant human IGFBP-3 also inhibited IGF-activated glucose consumption, without affecting insulin-stimulated glucose consumption. Glucose 55-62 insulin like growth factor binding protein 3 Homo sapiens 18-25 25490144-11 2015 Thus, overexpression of human IGFBP-3 or its mutant devoid of IGF binding ability leads to glucose intolerance with, however, different effects on insulin secretion, insulin sensitivity, and lipid homeostasis in aging mice. Glucose 91-98 insulin like growth factor binding protein 3 Homo sapiens 30-37 33087338-0 2020 Orai-IGFBP3 signaling complex regulates high-glucose exposure-induced increased proliferation, permeability, and migration of human coronary artery endothelial cells. Glucose 45-52 insulin like growth factor binding protein 3 Homo sapiens 5-11 33087338-2 2020 Our main objective is to reveal the potential mechanisms by which high-glucose (HG) exposure promotes increased proliferation of human coronary artery endothelial cells (HCAECs) in culture, and that store-operated Ca2+ entry (SOCE) and insulin-like growth factor binding protein 3 (IGFBP3) contribute to this proliferation. Glucose 71-78 insulin like growth factor binding protein 3 Homo sapiens 236-280 33087338-2 2020 Our main objective is to reveal the potential mechanisms by which high-glucose (HG) exposure promotes increased proliferation of human coronary artery endothelial cells (HCAECs) in culture, and that store-operated Ca2+ entry (SOCE) and insulin-like growth factor binding protein 3 (IGFBP3) contribute to this proliferation. Glucose 71-78 insulin like growth factor binding protein 3 Homo sapiens 282-288 29926665-6 2018 (2)The serum level of IGFBP-3 was down-regulated and IGF-1 activity was up-regulated while no change of serum total IGF-1 was induced by 4-week moderate aerobic exercise plus diet control, accompanied with significant decreases of body weight, BMI and waist circumference as well as improvement of glucose and lipid metabolism in the female obese youths and adolescents. Glucose 298-305 insulin like growth factor binding protein 3 Homo sapiens 22-29 33256349-7 2020 After adjustment of age, the IGF-I/IGFBP-3 ratio was significantly negatively associated with blood pressure and free thyroxine and positively associated with weight, hemoglobin, creatinine, alanine transferase, fasting glucose, and thyroid stimulating hormone. Glucose 220-227 insulin like growth factor binding protein 3 Homo sapiens 35-42 30328477-4 2018 Cells in high glucose were treated with exchange protein for cAMP 1 (Epac1) and IGFBP-3 siRNA. Glucose 14-21 insulin like growth factor binding protein 3 Homo sapiens 80-87 20610601-13 2010 CONCLUSIONS: Treatment with IGF-I/IGFBP-3 improved whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production. Glucose 62-69 insulin like growth factor binding protein 3 Homo sapiens 34-41 25525174-7 2014 RESULTS: Our results show that treatment with pioglitazone restored the high glucose-induced decrease in IGFBP-3 levels. Glucose 77-84 insulin like growth factor binding protein 3 Homo sapiens 105-112 22247904-5 2011 IGF-1 and IGFBP-3 levels were correlated with WC, hip circumference (HC), fasting glucose, TG, HDL-C, fasting insulin, and HOMA-IR. Glucose 82-89 insulin like growth factor binding protein 3 Homo sapiens 10-17 21447640-12 2011 Thus, overexpression of hIGFBP-3 in mice delays in vivo insulin clearance and reduces glucose-stimulated insulin secretion in pancreatic islets by both IGF-dependent and IGF-independent mechanisms. Glucose 86-93 insulin like growth factor binding protein 3 Homo sapiens 24-32 20610601-0 2010 Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance. Glucose 81-88 insulin like growth factor binding protein 3 Homo sapiens 46-67 24825082-9 2014 These findings suggest that IGFBP-3 may be involved in the glucose control and lipid metabolism in those with uncontrolled T1DM. Glucose 59-66 insulin like growth factor binding protein 3 Homo sapiens 28-35 23557743-0 2013 DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose. Glucose 113-120 insulin like growth factor binding protein 3 Homo sapiens 26-33 23592916-0 2013 Insulin-like growth factor binding protein-3 inhibits monocyte adhesion to retinal endothelial cells in high glucose conditions. Glucose 109-116 insulin like growth factor binding protein 3 Homo sapiens 0-44 23592916-5 2013 RESULTS: In high ambient glucose, overexpression of IGFBP-3 in RECs significantly decreased ICAM-1 expression when compared to the TNF-alpha-treated samples, whereas TNF-alpha increased monocyte-endothelial cell adhesion. Glucose 25-32 insulin like growth factor binding protein 3 Homo sapiens 52-59 23592916-6 2013 IGFBP-3 significantly decreased monocyte adhesion to RECs in the high glucose condition. Glucose 70-77 insulin like growth factor binding protein 3 Homo sapiens 0-7 23383064-5 2013 In human adipocytes, we show that IGFBP-3 inhibits TNF-alpha-induced NF-kappaB activity in an IGF-independent manner, thereby restoring the deregulated insulin signaling and negating TNF-alpha-induced inhibition of glucose uptake. Glucose 215-222 insulin like growth factor binding protein 3 Homo sapiens 34-41 23383064-6 2013 IGFBP-3 further inhibits TNF-alpha, CRP and high glucose-induced NF-kappaB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. Glucose 49-56 insulin like growth factor binding protein 3 Homo sapiens 0-7 23383064-6 2013 IGFBP-3 further inhibits TNF-alpha, CRP and high glucose-induced NF-kappaB activity in human aortic endothelial cells (HAECs) and subsequently suppresses monocyte adhesion to HAEC through the IGFBP-3 receptor. Glucose 49-56 insulin like growth factor binding protein 3 Homo sapiens 192-199 22539223-7 2012 RESULTS: CG-5 and glucose deprivation upregulated the expression of DNA methylation-silenced tumor suppressor genes, including GADD45a, GADD45b, IGFBP3, LAMB3, BASP1, GPX3, and GSTP1, but also downregulated methylated tumor/invasion-promoting genes, including CD44, S100A4, and TACSTD2. Glucose 18-25 insulin like growth factor binding protein 3 Homo sapiens 145-151 22482470-10 2012 Consistent with human tear measurements in vivo, IGFBP3 secretion was increased 2.2 fold (P<0.001) following culture of hTCEpi cells under elevated glucose conditions in vitro. Glucose 151-158 insulin like growth factor binding protein 3 Homo sapiens 49-55 22482470-11 2012 Treatment with glucose and the mannitol control reduced IGFBP3 mRNA (P<0.001). Glucose 15-22 insulin like growth factor binding protein 3 Homo sapiens 56-62 21711374-11 2012 Insulin and glucose were negatively associated with SHBG levels, as well as IGF-1 and IGF-BP3, while no associations were found with free thyroid hormone status. Glucose 12-19 insulin like growth factor binding protein 3 Homo sapiens 86-93 20610601-4 2010 OBJECTIVE: Our objective was to determine whether IGF-I, complexed to its major binding protein, IGF-binding protein-3 (IGFBP-3), improves glucose metabolism and alters body fat distribution in HIV-infected patients with abdominal obesity and insulin resistance. Glucose 139-146 insulin like growth factor binding protein 3 Homo sapiens 97-118 20610601-4 2010 OBJECTIVE: Our objective was to determine whether IGF-I, complexed to its major binding protein, IGF-binding protein-3 (IGFBP-3), improves glucose metabolism and alters body fat distribution in HIV-infected patients with abdominal obesity and insulin resistance. Glucose 139-146 insulin like growth factor binding protein 3 Homo sapiens 120-127 20610601-13 2010 CONCLUSIONS: Treatment with IGF-I/IGFBP-3 improved whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production. Glucose 81-88 insulin like growth factor binding protein 3 Homo sapiens 34-41 20610601-13 2010 CONCLUSIONS: Treatment with IGF-I/IGFBP-3 improved whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production. Glucose 81-88 insulin like growth factor binding protein 3 Homo sapiens 34-41 16873702-0 2006 Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Glucose 68-75 insulin like growth factor binding protein 3 Homo sapiens 35-56 19279229-5 2009 Moreover, IGFBP-3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF. Glucose 46-53 insulin like growth factor binding protein 3 Homo sapiens 10-17 17785698-4 2007 Recombinant human IGF-I alone or combined with its binding protein (IGFBP-3) provides an alternative therapy as IGF-I receptor shares structural and functional homology with the insulin receptor and recombinant human insulin-like growth factor I (rhIGF-I) therapy could improve glucose disposal by signalling through the IGF-I receptor, whilst reducing the adverse effects of high insulin concentrations. Glucose 278-285 insulin like growth factor binding protein 3 Homo sapiens 68-75 17426090-3 2007 OBJECTIVES: The aim was to determine the dose of rhIGF-I/rh-IGFBP-3 necessary to achieve a significant decrease in glucose and to determine the changes that occur in the IGF-II and acid labile subunit in response to treatment. Glucose 115-122 insulin like growth factor binding protein 3 Homo sapiens 60-67 17003344-5 2006 While IGF-I marginally increased peripheral glucose uptake, IGFBP-3 significantly decreased peripheral glucose uptake (approximately 30%, P < 0.01). Glucose 103-110 insulin like growth factor binding protein 3 Homo sapiens 60-67 16873702-2 2006 We used stable isotopes to investigate the effects of rhIGF-I/IGFBP-3 on glucose and glycerol metabolism in type 1 diabetes. Glucose 73-80 insulin like growth factor binding protein 3 Homo sapiens 62-69 16873702-6 2006 During the overnight basal steady state, rhIGF-I/IGFBP-3 dose-dependently reduced endogenous glucose production rate (R(a)) (P = 0.004), while peripheral glucose uptake (R(d)) was not different from placebo. Glucose 93-100 insulin like growth factor binding protein 3 Homo sapiens 49-56 16873702-7 2006 The increase in glucose R(d) during hyperinsulinemic clamp was greater following rhIGF-I/IGFBP-3 than placebo, both during the first (P = 0.008) and second step (P = 0.008) of the clamp. Glucose 16-23 insulin like growth factor binding protein 3 Homo sapiens 89-96 16873702-9 2006 In conclusion, rhIGF-I/IGFBP-3 enhances glucose metabolism by controlling both endogenous glucose output and peripheral glucose uptake. Glucose 40-47 insulin like growth factor binding protein 3 Homo sapiens 23-30 16873702-9 2006 In conclusion, rhIGF-I/IGFBP-3 enhances glucose metabolism by controlling both endogenous glucose output and peripheral glucose uptake. Glucose 90-97 insulin like growth factor binding protein 3 Homo sapiens 23-30 16873702-9 2006 In conclusion, rhIGF-I/IGFBP-3 enhances glucose metabolism by controlling both endogenous glucose output and peripheral glucose uptake. Glucose 90-97 insulin like growth factor binding protein 3 Homo sapiens 23-30 16776662-11 2006 CONCLUSION: Our data show that IGFBP-1, IGFBP-3 and IGF-I show acute changes following a glucose load and there are marked gender differences in these responses. Glucose 89-96 insulin like growth factor binding protein 3 Homo sapiens 40-47 16893376-9 2006 The levels of the anti-inflammatory cytokine transforming growth factor-beta1 and insulin-like growth factor binding protein 3 were lowered in patients with CAD and, in patients with PAD, the former was inversely related to the levels of the blood glucose. Glucose 248-255 insulin like growth factor binding protein 3 Homo sapiens 82-126 10597881-3 1999 The aim of the present study is to evaluate whether menopause and body mass index (BMI) affect the response of growth hormone (GH), insulin-like growth factor-binding protein-1 (IGFBP-1) and -3 (IGFBP-3) to the oral glucose tolerance test (OGTT). Glucose 216-223 insulin like growth factor binding protein 3 Homo sapiens 195-202 15935983-6 2005 Anti-sense IGFBP-3 oligo at 10 microg/mL significantly inhibited apoptosis induced by 100 ng/mL TNF-alpha, serum-free conditions, or high (25 mM) glucose. Glucose 146-153 insulin like growth factor binding protein 3 Homo sapiens 11-18 15935983-7 2005 Increased IGFBP-3 release associated with high ambient glucose or TNF-alpha was inhibited by pre-treatment with anti-sense oligo. Glucose 55-62 insulin like growth factor binding protein 3 Homo sapiens 10-17 12496045-10 2002 After adjusting for insulin, glucose, body mass index, and IGF-I, premenopausal women in the highest quartile of IGFBP-3 had an elevated risk of breast cancer [odds ratio (OR) = 5.28, 95% confidence interval (CI) = 1.13-24.7]. Glucose 29-36 insulin like growth factor binding protein 3 Homo sapiens 113-120 11551849-9 2001 We propose that, in catabolic, postoperative patients, increased levels of insulin from exogenous or, possibly, endogenous sources (nutritionally induced) may be a signal to increase IGF-I bioavailability by increased expression of IGFBP-3-PA to counteract further deterioration in glucose metabolism. Glucose 282-289 insulin like growth factor binding protein 3 Homo sapiens 232-239 11161963-7 2000 The mean 24 h blood glucose level (determined hourly) was the only parameter studied that significantly predicted the changes in mean 24 h IGFBP-3-PA in the diabetes group. Glucose 20-27 insulin like growth factor binding protein 3 Homo sapiens 139-146 16459470-1 2005 There is a strong relationship between ghrelin, insulin, glucose and IGF-I/IGFBP-3 metabolism. Glucose 57-64 insulin like growth factor binding protein 3 Homo sapiens 75-82 11925670-15 2002 Contrary to GH, baseline IGFBP-3 values correlated: with HOMAIR (+0.5002), with insulin/glucose (+0.4860). Glucose 88-95 insulin like growth factor binding protein 3 Homo sapiens 25-32 10447524-7 1999 Intermittently high glucose increased thymidine incorporation a further 58 % (p < 0.001), collagen synthesis by 65 % (p < 0.01) and insulin-like growth factor binding protein 3 secretion by 216 % (p < 0.01). Glucose 20-27 insulin like growth factor binding protein 3 Homo sapiens 138-182 10573632-5 1999 IGFBP-3 levels correlated significantly (0.91, p < 0.001) with GH suppressibility by glucose after surgery. Glucose 88-95 insulin like growth factor binding protein 3 Homo sapiens 0-7 10070009-1 1999 Insulin-like growth factor-binding protein-3 (IGFBP-3) was digested with plasmin, and the proteolytic fragments were isolated by HPLC and tested for bioactivity as measured by stimulation of glucose uptake in microvessel endothelial cells. Glucose 191-198 insulin like growth factor binding protein 3 Homo sapiens 0-44 10070009-1 1999 Insulin-like growth factor-binding protein-3 (IGFBP-3) was digested with plasmin, and the proteolytic fragments were isolated by HPLC and tested for bioactivity as measured by stimulation of glucose uptake in microvessel endothelial cells. Glucose 191-198 insulin like growth factor binding protein 3 Homo sapiens 46-53 9661636-4 1998 Eight patients receiving an oral glucose load before surgery demonstrated a significant greater relative increase in IGFBP-3-PA compared with 10 patients not receiving glucose (32.9 +/- 7.1% vs. 8.6 +/- 6.7%, respectively; P < 0.05). Glucose 33-40 insulin like growth factor binding protein 3 Homo sapiens 117-124